Unknown

Dataset Information

0

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.


ABSTRACT: Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies. As such, inhibiting HER3 could have broad applicability to the treatment of EGFR- and HER2-driven tumors. Although lack of a functional kinase domain limits the use of receptor tyrosine kinase inhibitors, HER3 contains antigenic targets for T cells and antibodies. Using novel human HER3 transgenic mouse models of breast cancer, we demonstrate that immunization with recombinant adenoviral vectors encoding full length human HER3 (Ad-HER3-FL) induces HER3-specific T cells and antibodies, alters the T cell infiltrate in tumors, and influences responses to immune checkpoint inhibitions. Both preventative and therapeutic Ad-HER3-FL immunization delayed tumor growth but were associated with both intratumoral PD-1 expressing CD8+ T cells and regulatory CD4+ T cell infiltrates. Immune checkpoint inhibition with either anti-PD-1 or anti-PD-L1 antibodies increased intratumoral CD8+ T cell infiltration and eliminated tumor following preventive vaccination with Ad-HER3-FL vaccine. The combination of dual PD-1/PD-L1 and CTLA4 blockade slowed the growth of tumor in response to Ad-HER3-FL in the therapeutic model. We conclude that HER3-targeting vaccines activate HER3-specific T cells and induce anti-HER3 specific antibodies, which alters the intratumoral T cell infiltrate and responses to immune checkpoint inhibition.

SUBMITTER: Osada T 

PROVIDER: S-EPMC5486174 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.

Osada Takuya T   Morse Michael A MA   Hobeika Amy A   Diniz Marcio A MA   Gwin William R WR   Hartman Zachary Z   Wei Junping J   Guo Hongtao H   Yang Xiao-Yi XY   Liu Cong-Xiao CX   Kaneko Kensuke K   Broadwater Gloria G   Lyerly H Kim HK  

Oncoimmunology 20170412 6


Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies. As such, inhibiting HER3 could have broad applicability to the treatment of EGFR- and HER2-driven tumors. Although lack of a functional kinase domain limits the use of receptor tyrosine kinase inhibitors, HER3 contains antigenic targets for T cells and antibodies. Using novel human HER3 transgen  ...[more]

Similar Datasets

| S-EPMC11910234 | biostudies-literature
| S-EPMC8719891 | biostudies-literature
| S-EPMC10351710 | biostudies-literature
| S-EPMC8137908 | biostudies-literature
| S-EPMC8656934 | biostudies-literature
| S-EPMC10944859 | biostudies-literature
| S-EPMC4855657 | biostudies-literature
| S-EPMC8562569 | biostudies-literature
| S-EPMC11178024 | biostudies-literature
| S-EPMC11364395 | biostudies-literature